RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Clinical trials for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Shielding vulnerable patients: new strategy to block dangerous infections during cancer therapy
Disease control Recruiting nowThis study is testing whether a drug called letermovir can prevent serious CMV infections in adults with relapsed or hard-to-treat multiple myeloma. Participants, who have already had several other treatments, will receive letermovir while undergoing a new immunotherapy called el…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
New drug combo tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing whether adding a drug called Epunamin to a standard chemotherapy regimen (DECP) can help control multiple myeloma that has returned or stopped responding to previous treatments. The trial will enroll 48 adults with relapsed/refractory multiple myeloma to see…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Sponsor: Shanxi Bethune Hospital • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
New hope for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing how safe and effective a combination of two new drugs, mezigdomide and elranatamab, is for people with multiple myeloma that has come back or stopped responding to other treatments. The first part of the study will find the best dose, and the second part wil…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE1, PHASE2 • Sponsor: YOUNGIL KOH • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New combo therapy tested for advanced blood cancer
Disease control Recruiting nowThis study is testing if a combination of two drugs, elranatamab and isatuximab, can help control multiple myeloma that has returned or stopped responding to other treatments. It will enroll 30 adults whose cancer has progressed after at least two prior therapies. The goal is to …
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC
-
New hope for Tough-to-Treat blood cancer: experimental drug enters final testing phase
Disease control Recruiting nowThis study is testing an experimental drug called linvoseltamab for people whose multiple myeloma has returned after prior treatments. It will compare linvoseltamab to a standard combination of three other cancer drugs. The goal is to see which treatment is more effective at cont…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC
-
Researchers track Real-World results for advanced blood cancer treatments
Knowledge-focused Recruiting nowThis study aims to understand how two newer drugs, teclistamab and talquetamab, work for patients with advanced multiple myeloma in real-world settings, outside of controlled clinical trials. Researchers will collect and analyze health records from about 900 patients who have alr…
Matched conditions: RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
Sponsor: Janssen-Cilag Ltd. • Aim: Knowledge-focused
Last updated Apr 04, 2026 03:06 UTC